250 related articles for article (PubMed ID: 33194599)
1. What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk?
Gao W; Du J; Liu J; Zhou H; Zhang Z; Jian Y; Yang G; Wang G; Tian Y; Li Y; Wu Y; Fu W; Li J; Chen W
Front Oncol; 2020; 10():538126. PubMed ID: 33194599
[TBL] [Abstract][Full Text] [Related]
2. Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China.
Gao W; Jian Y; Du J; Li X; Zhou H; Zhang Z; Yang G; Wang G; Tian Y; Li Y; Wu Y; Fu W; Li J; Chen W
Cancer Med; 2020 Nov; 9(21):7819-7829. PubMed ID: 32881351
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
4. Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment.
Minguela A; Vasco-Mogorrón MA; Campillo JA; Cabañas V; Remigia MJ; Berenguer M; García-Garay MC; Blanquer M; Cava C; Galian JA; Gimeno L; Soto-Ramírez MF; Martínez-Hernández MD; de la Rubia J; Teruel AI; Muro M; Periago A
Am J Cancer Res; 2021; 11(9):4438-4454. PubMed ID: 34659897
[TBL] [Abstract][Full Text] [Related]
5. The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain.
Tang HKK; Fung CY; Morgan GJ; Kumar S; Siu L; Ip HWA; Yip SF; Lau KNH; Lau CK; Lee H; Leung KH; Kho B; Wong H; Ngai C; Hwang YY; Sim J; Kwong YL; Chim CS
Ther Adv Hematol; 2022; 13():20406207221082043. PubMed ID: 35465644
[TBL] [Abstract][Full Text] [Related]
6. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.
Varma A; Sui D; Milton DR; Tang G; Saini N; Hasan O; Mukherjee A; Joseph JJ; Bashir Q; Rondon G; Srour S; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Mehta R; Khouri IF; Ahmed H; Iyer S; Weber DM; Thomas SK; Manasanch E; Lee HC; Patel K; Ciurea SO; Shpall EJ; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2020 Apr; 26(4):665-671. PubMed ID: 31881283
[TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21.
Nahi H; Våtsveen TK; Lund J; Heeg BM; Preiss B; Alici E; Møller MB; Wader KF; Møller HE; Grøseth LA; Østergaard B; Dai HY; Holmberg E; Gahrton G; Waage A; Abildgaard N
Eur J Haematol; 2016 Jan; 96(1):46-54. PubMed ID: 25779478
[TBL] [Abstract][Full Text] [Related]
8. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
[TBL] [Abstract][Full Text] [Related]
9. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma.
Mohan M; Gong Z; Ashby TC; Al Hadidi S; Thanendrarajan S; Schinke C; Alapat D; Shaughnessy JD; Zhan F; van Rhee F; Sawyer JR; Tian E; Zangari M
Cancer; 2023 Aug; 129(16):2491-2498. PubMed ID: 37282609
[TBL] [Abstract][Full Text] [Related]
10. Presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies: results from a single-center study.
Chen H; Zhou N; Shi H; Yu W; Wu L; Zhou F
Hematology; 2023 Dec; 28(1):2177979. PubMed ID: 36794720
[TBL] [Abstract][Full Text] [Related]
11. The independent adverse prognostic significance of 1q21 gain/amplification in newly diagnosed multiple myeloma patients.
You H; Jin S; Wu C; Wang Q; Yan S; Yao W; Shi X; Shang J; Yan L; Yao Y; Wang J; Wang P; Pan J; Wu D; Fu C
Front Oncol; 2022; 12():938392. PubMed ID: 36276097
[TBL] [Abstract][Full Text] [Related]
12. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.
Dhakal B; Szabo A; Chhabra S; Hamadani M; D'Souza A; Usmani SZ; Sieracki R; Gyawali B; Jackson JL; Asimakopoulos F; Hari PN
JAMA Oncol; 2018 Mar; 4(3):343-350. PubMed ID: 29302684
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of the efficacy and prognosis on first-line autologous hematopoietic stem cell transplantation of patients with multiple myeloma].
Zou DH; Sui WW; Yi SH; An G; Xu Y; Li ZJ; Li CW; Qi JY; Zhao YZ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):299-303. PubMed ID: 23668200
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
Wang H; Meng H; Wang J; Lou Y; Zhou Y; Lin P; Li F; Liu L; Xu H; Yang M; Jin J
Front Med; 2020 Jun; 14(3):327-334. PubMed ID: 31784918
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of post-transplant bone marrow plasma cell percent in multiple myeloma patients undergone autologous transplantation.
Hwang IH; Chung JS; Shin HJ; Choi YJ; Song MK; Seol YM; Cho GJ; Choi BG; Choi MK; Choi BK; Ahn KH; Shin KH; Lee HS; Nam HS; Hwang JM
Korean J Intern Med; 2011 Mar; 26(1):76-81. PubMed ID: 21437166
[TBL] [Abstract][Full Text] [Related]
16. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
Grzasko N; Hus M; Pluta A; Jurczyszyn A; Walter-Croneck A; Morawska M; Chocholska S; Hajek R; Dmoszynska A
Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
[TBL] [Abstract][Full Text] [Related]
17. Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis.
Wang YT; Bao L; Chu B; Chen XH; Lu MQ; Shi L; Gao S; Fang LJ; Xiang QQ; Ding YH
J Clin Lab Anal; 2022 Jul; 36(7):e24375. PubMed ID: 35353920
[TBL] [Abstract][Full Text] [Related]
18. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.
Nemec P; Zemanova Z; Greslikova H; Michalova K; Filkova H; Tajtlova J; Kralova D; Kupska R; Smetana J; Krejci M; Pour L; Zahradova L; Sandecka V; Adam Z; Buchler T; Spicka I; Gregora E; Kuglik P; Hajek R
Biol Blood Marrow Transplant; 2010 Apr; 16(4):548-54. PubMed ID: 20005965
[TBL] [Abstract][Full Text] [Related]
19. Genomic aberrations and survival of patients with light-chain-only multiple myeloma undergoing autologous stem cell transplantation.
Jiang N; Qi C; Trieu Y; Reece D; Chang H
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1790-5. PubMed ID: 21658460
[TBL] [Abstract][Full Text] [Related]
20. [Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients].
Liu XL; Yang PY; Yu XY; Chen JC; Liu XL; Bai J; Liu YM; He H; Sun JN; Fan HQ; Zhang C; Zhang Y; Su KJ; Liu CS; Tan YH; Gao SJ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):408-413. PubMed ID: 29779352
[No Abstract] [Full Text] [Related]
[Next] [New Search]
